{
    "organizations": [],
    "uuid": "bfd94752524bea0f797c3aebed56f434d9504e40",
    "author": "",
    "url": "https://www.reuters.com/article/brief-kyowa-kirin-ultragenyx-announce-cr/brief-kyowa-kirin-ultragenyx-announce-crysvita-receives-conditional-marketing-authorization-in-europe-for-the-treatment-of-xlinked-hypophosphatemia-in-children-idUSFWN1QD0U5",
    "ord_in_thread": 0,
    "title": "BRIEF-Kyowa Kirin, Ultragenyx Announce Crysvita Receives Conditional Marketing Authorization In Europe For The Treatment Of X–Linked Hypophosphatemia In Children",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "Market News  10 PM / in 8 minutes BRIEF-Kyowa Kirin, Ultragenyx Announce Crysvita Receives Conditional Marketing Authorization In Europe For The Treatment Of X–Linked Hypophosphatemia In Children Reuters Staff 1 Min Read Feb 23 (Reuters) - Ultragenyx Pharmaceutical Inc: * KYOWA KIRIN AND ULTRAGENYX ANNOUNCE CRYSVITA® (BUROSUMAB) RECEIVES CONDITIONAL MARKETING AUTHORIZATION IN EUROPE FOR THE TREATMENT OF X–LINKED HYPOPHOSPHATEMIA IN CHILDREN * ULTRAGENYX PHARMACEUTICAL - ‍FIRST COMMERCIAL LAUNCH OF CRYSVITA IS EXPECTED TO TAKE PLACE IN GERMANY IN Q2 OF 2018​ Source text for Eikon:  ",
    "published": "2018-02-23T15:09:00.000+02:00",
    "crawled": "2018-02-23T15:24:10.072+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "market",
        "news",
        "pm",
        "minute",
        "kirin",
        "ultragenyx",
        "announce",
        "crysvita",
        "receives",
        "conditional",
        "marketing",
        "authorization",
        "europe",
        "treatment",
        "hypophosphatemia",
        "child",
        "reuters",
        "staff",
        "min",
        "read",
        "feb",
        "reuters",
        "ultragenyx",
        "pharmaceutical",
        "inc",
        "kyowa",
        "kirin",
        "ultragenyx",
        "announce",
        "burosumab",
        "receives",
        "conditional",
        "marketing",
        "authorization",
        "europe",
        "treatment",
        "hypophosphatemia",
        "child",
        "ultragenyx",
        "pharmaceutical",
        "commercial",
        "launch",
        "crysvita",
        "expected",
        "take",
        "place",
        "germany",
        "q2",
        "source",
        "text",
        "eikon"
    ]
}